Corvus Pharmaceuticals Confirms Planned Initiation Of Soquelitinib Phase 3 Registrational Clinical Trial In Peripheral T Cell Lymphoma Following Meeting With FDA
Plans to initiate soquelitinib potentially registrational Phase 3 clinical trial in Q1 2024
Company to host conference call and webcast tomorrow at 8:30 a.m. ET / 5:30 a.m. PT
BURLINGAME, Calif., Sept. 06,